Adenoid cystic carcinoma (ACC) is a rare, insidious malignancy, most commonly originating in the salivary glands, that presents unique diagnostic and therapeutic challenges. Recent decades have seen a ...
REHOVOT, Israel & WILMINGTON, Del., June 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule ...
“Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]” In general, tumors originating from the minor salivary glands often ...
Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). This is an ...
A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing ...
Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader ...
WATERTOWN, Mass., Oct. 16, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying ...
PIN-5018 achieves complete response in ACC PDX models Expansion planned into mCRPC, colorectal cancer, and other rare tumours ...
- REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML - Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback